Clinical Trials Logo

Clinical Trial Summary

The overall aim of this study is to prospectively validate the superiority of the Immunoscore as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in comparison to the conventional TNM-based high- or low-risk classification.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04488159
Study type Interventional
Source Medical University of Vienna
Contact Johannes Laengle, MD, PhD
Phone +43 1 40400 69260
Email johannes.laengle@meduniwien.ac.at
Status Not yet recruiting
Phase Phase 3
Start date December 1, 2024
Completion date June 1, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT00309530 - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C Phase 3
Completed NCT04342676 - Lymph Node Ratio and Kras Mutation in R Colon Cancer Phase 3
Enrolling by invitation NCT05179889 - Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer Phase 2/Phase 3
Withdrawn NCT05433402 - Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer Phase 1/Phase 2
Recruiting NCT06108310 - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Recruiting NCT05310565 - The Effects of Chiropractic in Adults With Colon Cancer N/A
Recruiting NCT05194878 - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers Phase 3